Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To investigate whether a reduced-dose dosing regimen (1x500mg semiannually) of rituximab (RTX) (Mabthera®) is non-inferior in patients with rheumatoid arthritis (RA) whose disease is in persistent low disease activity (LDA) or clinical remission (REM) (pLDA/pREM) as compared to the standard dosing regimen of 1x1000mg semi-annual infusions.
Critère d'inclusion
- Rheumatoid Arthritis